112253-70-0

Basic information

• Product Name: 2-Amino-4-bromobenzamide
• Synonyms: 2-Amino-4-bromobenzamide;4-Bromoanthranilamide;Benzamide, 2-amino-4-bromo-
• CAS NO: 112253-70-0
• Molecular Formula: C₇H₇BrN₂O
• Molecular Weight: 215.049
• Mol File: 112253-70-0.mol

Chemical Properties

• Melting Point: 176-177℃
• Boiling Point: 318.808°C at 760 mmHg
• Flash Point: 146.61°C
• Appearance: /
• Density: 1.699g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.667
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 15.48±0.50(Predicted)
• CAS DataBase Reference: 2-Amino-4-bromobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-bromobenzamide(112253-70-0)
• EPA Substance Registry System: 2-Amino-4-bromobenzamide(112253-70-0)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 112253-70-0(Hazardous Substances Data)

Usage

Uses

2-Amino-4-bromobenzamide is a useful synthetic compound.

InChI:InChI=1/C7H7BrN2O/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3H,9H2,(H2,10,11)

Upstream product

• 20776-50-5 2-amino-4-bromobenzoic acid 
• 79603-03-5 4-bromo-2-nitro-benzonitrile 
• 304858-65-9 2-amino-4-bromobenzonitrile 
• 1152237-09-6 4-bromo-2-nitrobenzamide 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 76561-16-5 7-bromo-1,2-dihydro-3,1-4H-benzoxazine-2,4-dione 
• 6326-79-0 6-bromoisatin 

Downstream Products

• 194851-16-6 7-bromoquinazolin-4(3H)-one 
• 1152237-10-9 C₁₄H₉BrN₂O 
• 1354455-85-8 C₁₂H₁₅BrN₂O₂ 
• 1354455-79-0 N-{4-[2-tert-Butyl-4-(6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-quinazolin-7-yl]-phenyl}-methanesulfonamide 
• 1354455-87-0 C₁₉H₂₁N₃O₃S 
• 1354455-88-1 N-[4-(2-tert-butyl-4-chloroquinazolin-7-yl)phenyl]methanesulfonamide 
• 1354455-89-2 C₂₆H₂₈N₄O₃S 
• 1357259-12-1 C₂₀H₁₈BrN₃O₃ 
• 1357259-14-3 C₄₂H₄₂N₆O₅ 
• 1357259-18-7 C₄₄H₄₅N₇O₆ 
• 1357258-58-2 C₄₉H₅₄N₈O₇ 
• 1357258-59-3 C₄₆H₄₈N₈O₇ 
• 1357258-60-6 C₅₀H₅₄N₈O₇ 
• 1357258-61-7 C₄₉H₅₂N₈O₇ 

Relevant articles and documents

COMPOUNDS AND METHODS FOR MODULATING SPLICING

The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e g., splicing of a pre-mRNA, as well as methods of use thereof.

Synthesis and nematicidal activities of 1,2,3-benzotriazin-4-one containing 4,5-dihydrothiazole-2-thiol derivatives against Meloidogyne incognita

A series of novel 1,2,3-benzotriazin-4-one derivatives containing 4,5-dihydrothiazole-2-thiol were synthesized and characterized by 1H NMR, 13C NMR, 19F NMR and HRMS. The bioassay results showed that compounds 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-7-methoxybenzo[d][1–3]triazin-4(3H)-one, 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-6-nitrobenzo[d][1–3]triazin-4(3H)-one, 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one exhibited good control efficacy against the cucumber root-knot nematode disease caused by Meloidogyne incognita at the concentration of 10.0 mg L?1 in vivo. Compound 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one showed excellent nematicidal activity with inhibition 68.3% at a concentration of 1.0 mg L?1. It suggested that the structure of 1,2,3-benzotriazin-4-one containing 4,5-dihydro-thiazole-2-thiol could be optimized further.

Oxidative ring-opening of isatins for the synthesis of 2-aminobenzamides and 2-aminobenzoates

An efficient and practical isatin-based oxidative domino protocol has been developed for the facile synthesis of 2-aminobenzamides and 2-aminobenzoates. The robust nature of this reaction system is reflected by accessible starting materials, room temperature and high-yield gram-scale synthesis.

Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors

Transient receptor potential melastatin 2 (TRPM2), a Ca2+-permeable cationic channel, plays critical roles in insulin release, cytokine production, body temperature regulation and cell death as a reactive oxygen species (ROS) and temperature sensor. However, few TRPM2 inhibitors have been reported, especially TRP-subtype selective inhibitors, which hampers the investigation and validation of TRPM2 as a drug target. To discover novel TRPM2 inhibitors, 3D similarity-based virtual screening method was employed, by which 2,3-dihydroquinazolin-4(1H)-one derivative H1 was identified as a TRPM2 inhibitor. A series of novel 2,3-dihydroquinazolin-4(1H)-one derivatives were subsequently synthesized and characterized. Their inhibitory activities against the TRPM2 channel were evaluated by calcium imaging and electrophysiology approaches. Some of the compounds exhibited significant inhibitory activity, especially D9 which showed an IC50 of 3.7 μM against TRPM2 and did not affect the TRPM8 channel. The summarized structure-activity relationship (SAR) provides valuable insights for further development of specific TRPM2 targeted inhibitors.

SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS

The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

Synthesis and Nematicidal Activities of 1,2,3-Benzotriazin-4-one Derivatives against Meloidogyne incognita

A series of novel 1,2,3-benzotriazin-4-one derivatives were synthesized by the reaction of 3-bromoalkyl-1,2,3-benzotriazin-4-ones with potassium salt of 2-cyanoimino-4-oxothiazolidine in the presence of potassium iodide. Nematicidal assays in vivo showed that some of them exhibited good control efficacy against the cucumber root-knot nematode disease caused by Meloidogyne incognita, up to 100% at the concentration of 10.0 mg L-1, which indicated that 1,2,3-benzotriazin-4-one derivatives might be potential for novel promising nematicides. The nematicidal activity was influenced by the combination of substituent type, substituted position, and linker length in the molecule. The inhibition rate data at the concentrations of 5.0 and 1.0 mg L-1 for the compounds with high inhibitory activities were also provided. When tested in vitro, none of them showed direct inhibition against M. incognita. The investigation of a significant difference between in vivo and in vitro data is in progress.

HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors,in HCV therapy.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

An improved method for the conversion of nitriles to amides using N,N-disubstituted hydroxylamine

An improved method for the selective hydration of nitriles to amides employing N,N-disubstituted hydroxylamine is described leading to a reduction in reaction time and improved yield. Amides having electron-donating groups, which were not reported using the original method, were obtained in excellent yields. The amount of N,N-disubstituted hydroxylamine was reduced from three equivalents to one equivalent and the use of water as the reaction medium is environmentally friendly.

Small Molecule Inhibitors of Toll-Like Receptor 9

Small molecule compounds and compositions containing said compounds useful for inhibiting signaling by certain Toll-like receptors (TLRs), particularly TLR9, are provided. The compounds and compositions can be used to inhibit immune responses, including unwanted immune responses in particular. Compounds, compositions, and methods are provided to treat a variety of conditions involving unwanted immune responses, including for example autoimmune disease, inflammation, transplant rejection, and sepsis.